timothy sykes logo
Moderna Stock Explodes After Landmark Cancer Vaccine Breakthrough Thumbnail
G Google News

Moderna Stock Explodes After Landmark Cancer Vaccine Breakthrough

TIM SYKES•UPDATED AUG. 21, 2026, 12:32 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Moderna Inc. stocks have been trading up by 11.52 percent following strong positive sentiment around its latest mRNA pipeline advances.

Key Takeaways

  • Late‑stage melanoma trial of personalized mRNA cancer vaccine intismeran autogene plus Keytruda met primary and key secondary endpoints, the first positive Phase 3 readout for an mRNA‑based cancer therapy.
  • Shares ripped as much as 177% on the topline melanoma data, briefly making MRNA the biggest gainer in the S&P 500.
  • Intraday and pre‑market spikes between roughly 54% and 142% show an aggressive market re‑rating and heavy risk‑on trading in MRNA.
  • Bank of America hiked its MRNA price target from $40 to $170, calling the melanoma result a watershed moment that broadens the story beyond infectious disease.
  • William Blair upgraded MRNA to Outperform, pointing to the melanoma program as a key driver of revenue diversification away from COVID‑focused products.

Candlestick Chart

Live Update At 12:32:26 EDT: On Friday, August 21, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 11.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA has gone from grind mode to rocket mode in a matter of days. The daily chart shows the stock trading around $55–$65 for weeks, then exploding from $63.04 on 2026/08/18 to a $176.66 intraday high on 2026/08/19 before closing at $174.38. The next sessions stayed wild, with closes at $133.32 and then $148.79 as traders fought over where this new value zone should be.

Under the hood, Moderna is still a high‑burn story. Quarterly revenue sits at about $145M, with total revenue over the last period reported at roughly $1.94B and shrinking versus prior years. Profitability is deep in the red: EBITDA at about -$734M and net income at -$782M for the quarter, plus free cash flow around -$563M. Yet MRNA holds serious cash and short‑term investments, roughly $5.14B, and has modest leverage with total debt to equity near 0.18.

More Breaking News

For traders, that mix matters. MRNA is not priced on current earnings; it trades on future pipeline. The INTerpath‑001 melanoma data just gave the market a new story, and the chart shows exactly how fast sentiment can flip when that story catches fire.

Why Traders Are Watching MRNA’s Melanoma Shockwave

MRNA and Merck just delivered what the market has been waiting for: proof that mRNA tech is more than a COVID trade. Their individualized cancer vaccine, intismeran autogene, combined with Keytruda, hit both the primary endpoint of recurrence‑free survival and a key secondary endpoint of distant metastasis‑free survival in fully resected stage IIB–IV melanoma. That makes this the first positive Phase 3 result ever for an mRNA‑based cancer therapy.

For biotech traders, that is a line‑in‑the‑sand moment. The data were described as statistically significant and clinically meaningful versus Keytruda alone, with no new safety issues. In plain language, the combo helped keep cancer from coming back or spreading, and it did so without introducing fresh red‑flag side effects in this dataset. That is the kind of risk‑reward setup that can reprice a whole platform, not just a single drug.

The tape backed that up. MRNA shares jumped 54% when the INTerpath‑001 trial first hit primary endpoints, then went on to surge as much as 177%, at one point making the stock the biggest gainer in the entire S&P 500. Other reports clocked spikes of 113.6%, 128.3%, and 142% as traders piled into the name across pre‑market and regular hours.

Wall Street quickly followed the price. Bank of America upgraded MRNA from Underperform to Neutral and yanked its target from $40 to $170, calling the melanoma readout a watershed moment that eases capital worries and broadens the story far beyond infectious disease. William Blair upgraded MRNA to Outperform on the same data, stressing how the program shifts the narrative toward oncology and away from a fading COVID revenue base.

Put it together, and you have a classic momentum trifecta: a first‑of‑its‑kind clinical win, a violent repricing on the chart, and heavyweight analysts rushing to reset expectations. That is why active traders are glued to every tick in MRNA right now.

Conclusion

MRNA just gave the market a masterclass in how fast sentiment can change when real data lands. One week, Moderna was another former COVID high‑flyer grinding around $60. Then the melanoma trial with Merck’s Keytruda hit, showing intismeran autogene delivered statistically significant and clinically meaningful gains in recurrence‑free and distant metastasis‑free survival, with no new safety signals. Overnight, MRNA turned into a poster child for mRNA‑driven oncology.

The price action says it all. A 177% surge, repeated reports of 50%–140% single‑session spikes, and MRNA briefly topping the S&P 500 leaderboard. Analyst upgrades from Bank of America and William Blair, along with a massive target hike to $170, reinforced the idea that traders are no longer valuing MRNA only on COVID cash flows. They are trading a platform with potential across multiple tumor types.

But parabolic charts cut both ways. MRNA still reports quarterly losses, negative free cash flow, and relies on future approvals to justify a rich price‑to‑sales ratio. That is why the Sykes‑style mindset matters here. As Tim Sykes likes to remind traders, “The market doesn’t care about your opinion, only the price action. Trade the pattern, not the story.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. For MRNA, the story just got a lot bigger—but disciplined traders will still let the chart, volume, and risk management call the shots. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”